Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity (Q39908130)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

15 September 2017

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity (English)

1 reference

Europe PubMed Central

15 September 2017

0 references

Stefania Landolfi

object named as

S Landolfi

8

0 references

11

object named as

J Baselga

1 reference

Europe PubMed Central

15 September 2017

author name string

M Scaltriti

1

1 reference

Europe PubMed Central

15 September 2017

C Verma

2

1 reference

Europe PubMed Central

15 September 2017

M Guzman

3

1 reference

Europe PubMed Central

15 September 2017

J Jimenez

4

1 reference

Europe PubMed Central

15 September 2017

J L Parra

5

1 reference

Europe PubMed Central

15 September 2017

K Pedersen

6

1 reference

Europe PubMed Central

15 September 2017

D J Smith

7

1 reference

Europe PubMed Central

15 September 2017

S Ramon y Cajal

9

1 reference

Europe PubMed Central

15 September 2017

J Arribas

10

1 reference

Europe PubMed Central

15 September 2017

language of work or name

0 references

publication date

8 December 2008

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

28

1 reference

Europe PubMed Central

15 September 2017

6

1 reference

Europe PubMed Central

15 September 2017

803-814

1 reference

Europe PubMed Central

15 September 2017

https://scigraph.springernature.com/pub.10.1038/onc.2008.432

0 references

Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

CHARMM: A program for macromolecular energy, minimization, and dynamics calculations

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

EGF-ERBB signalling: towards the systems level

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Association with membrane protrusions makes ErbB2 an internalization-resistant receptor

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Degradation of HER2 by Cbl-based chimeric ubiquitin ligases

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Comparative protein modelling by satisfaction of spatial restraints

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

TGFalpha expression impairs Trastuzumab-induced HER2 downregulation

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic m

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

2.2 A refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

21 January 2018

Targeting tyrosine kinases in cancer: the second wave

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

31 March 2020

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

31 March 2020

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

31 March 2020

The role of ErbB2 signaling in the onset of terminal differentiation of oligodendrocytes in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

31 March 2020

Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.432

31 March 2020

Identifiers

10.1038/ONC.2008.432

1 reference

Europe PubMed Central

15 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

15 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39908130&oldid=1876810791"